Weight Regain Following Discontinuation of GLP-1 Therapy

An important limitation emerging from current research on GLP-1 receptor agonists is the tendency for weight regain following treatment discontinuation. While these medications can produce substantial weight reduction during active therapy, maintaining those reductions once pharmacological support is removed remains a significant challenge.

Evidence suggests that the weight-reducing effects of GLP-1 therapies are primarily driven by ongoing neuroendocrine modulation of appetite and satiety pathways rather than permanent metabolic reprogramming. When treatment is discontinued, these pharmacological effects diminish, allowing many of the underlying physiological drivers of energy intake to re-emerge.

One of the most widely cited investigations of this phenomenon is the STEP-4 clinical trial, which evaluated the effects of withdrawing semaglutide after an initial treatment phase. Participants first received semaglutide for 20 weeks and achieved an average 10.6% reduction in body weight. They were then randomly assigned either to continue semaglutide or switch to placebo.

Over the subsequent 48 weeks:

• Participants who continued semaglutide lost an additional ~7.9% of body weight.

• Participants who switched to placebo regained approximately 6.9% of body weight despite ongoing lifestyle interventions.

These findings demonstrate that cessation of GLP-1 therapy is associated with a partial reversal of treatment-induced weight loss.

Similar findings have been reported in studies evaluating tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. In the SURMOUNT-4 trial, individuals who discontinued tirzepatide after significant weight reduction experienced progressive weight regain, whereas those who continued therapy maintained or further reduced body weight.

Together, these studies reinforce the concept that continued receptor activation may be necessary to sustain appetite suppression and long-term weight loss.

Physiological Drivers of Weight Regain

Weight regain following treatment discontinuation appears to be influenced by several interconnected biological mechanisms.

1. Restoration of Appetite Signalling

GLP-1 receptor agonists suppress appetite through central nervous system pathways involving the hypothalamus, hindbrain, and reward centres such as the nucleus accumbens. When pharmacological stimulation of these receptors stops, appetite signals gradually return to baseline levels, often resulting in increased hunger and greater caloric intake.

2. Hormonal Adaptations to Weight Loss

Weight reduction itself triggers compensatory endocrine responses designed to restore energy balance. These include:

• Increased levels of the hunger hormone ghrelin

• Reduced secretion of satiety hormones

• Alterations in leptin signalling

These hormonal adaptations can persist for extended periods following weight loss and are thought to contribute significantly to long-term weight regain.

3. Metabolic Adaptation

Weight loss is frequently accompanied by a reduction in resting metabolic rate, a phenomenon sometimes referred to as adaptive thermogenesis. As energy expenditure decreases, maintaining a reduced body weight becomes progressively more difficult without sustained behavioural or pharmacological support.

4. Changes in Body Composition

Rapid weight loss may involve reductions in both fat mass and lean body mass. Loss of skeletal muscle can further reduce metabolic rate, which may increase susceptibility to weight regain if nutritional intake and resistance exercise are not carefully maintained.

Implications for Long-Term Weight Management

The available evidence suggests that GLP-1 receptor agonists may function more similarly to chronic disease therapies rather than short-term weight-loss interventions. In this context, obesity is increasingly recognised as a condition requiring long-term management strategies, similar to hypertension or diabetes.

Current research is therefore exploring strategies that may improve long-term weight maintenance after GLP-1 therapy, including:

• Gradual dose tapering rather than abrupt discontinuation

• Combining pharmacotherapy with structured behavioural and nutritional interventions

• Development of next-generation incretin therapies, including dual and triple receptor agonists

Understanding how to maintain weight loss after treatment discontinuation remains an active area of investigation. As incretin-based therapies continue to evolve, identifying effective long-term management strategies will be critical to maximising their clinical benefit.

References

Wilding, J.P.H., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity.New England Journal of Medicine, 384, 989-1002.

Rubino, D., et al. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP-4 trial.JAMA, 325(14), 1414-1425.

Jastreboff, A.M., et al. (2022). Tirzepatide once weekly for the treatment of obesity.New England Journal of Medicine, 387, 205-216.

Reiss, A.B., et al. (2025). Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss.Biomolecules, 15(3), 408.